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Lack of FDG Uptake in Small Cell Carcinoma Associated
with ANNA-1 Positive Paraneoplastic Autonomic
Neuropathy
Matthew S. Block, MD, PhD,* and Robert Vassallo, MD*†‡
A 76-year-old smoker presented with profound weight loss due to
gastrointestinal dysmotility associated with high levels of the para-
neoplastic antibody ANNA-1. Serial computed tomography scans
showed regressing subcarinal adenopathy, and positron emission
tomography imaging showed mild fluorodeoxy-D-glucose uptake in
subcarinal nodes, suggestive of benign disease. Diagnosis of small
cell carcinoma was established by biopsy of mediastinal nodes. This
case highlights the importance of a thorough search for malignancy
in patients with high levels of circulating autoantibodies and sug-
gests that benign-appearing imaging studies be interpreted with
caution in patients with paraneoplastic autoimmune syndromes.
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The diagnosis of small cell carcinoma can only be estab-lished by tissue biopsy; however, the decision to proceed
to biopsy is generally guided by imaging findings. Small cell
carcinoma is an aggressive tumor that characteristically
causes avid fluorodeoxy-D-glucose (FDG) uptake on positron
emission tomography (PET) scanning. As a result, FDG-PET
and PET-computed tomography (CT) are commonly used in
the diagnostic workup of lung nodules suspected to be small
cell cancer, or in diagnostic staging. In a subgroup of patients
with small cell and other cancers, an autoimmune paraneo-
plastic syndrome may occur, resulting in neurologic manifes-
tations associated with circulating antibodies directed to a
variety of host antigens.1
Herein, we report a patient who presented with an
autonomic gastrointestinal motor neuropathy associated with
high levels of circulating type 1 antineuronal nuclear autoan-
tibodies (ANNA-1). Unexpectedly, the chest CT showed
subcarinal and mediastinal adenopathy, which partially re-
gressed upon longitudinal follow-up and demonstrated only
minimal uptake of FDG on PET scanning, suggesting benign
disease rather than malignancy. Definitive diagnosis was
established by direct biopsy of subcarinal adenopathy, which
demonstrated small cell carcinoma.
CASE REPORT
A 76-year-old man with a 120 pack-year smoking
history presented for evaluation of a 55 pound unintentional
weight loss over the preceding 13 months. Associated symp-
toms included dysphagia, diarrhea with fecal incontinence,
ataxia, and symptoms of a peripheral neuropathy. Prior
workup had included routine laboratory testing, indicative
only of mild microcytic anemia; a bone marrow biopsy, an
abdominal ultrasound, and a head MRI, each of which were
unremarkable. A chest CT obtained 9 months before presen-
tation showed a 9 mm pulmonary nodule and a 2-cm sub-
carinal (station 7) lymph node. A decision was made to
follow up these findings rather than biopsy, and a follow-up
scan 6 months before presentation showed stability of the
lung nodule and adenopathy.
On arrival at our institution, the patient underwent a
body CT scan, which revealed the prominent station-7 lymph
node had regressed significantly in size to 1 cm (Figure 1)
whereas the previously noted 9-mm pulmonary nodule was
unchanged. Further evaluation of the chest CT findings was
undertaken with PET-CT, which showed mild FDG uptake in
both the pulmonary nodule and at station 7 [maximum SUV
1.4], and was radiographically considered as distinctly un-
likely to be malignant (Figure 2). No other foci of high FDG
uptake were found. Because of the patient’s neurologic symp-
toms suggestive of autonomic and peripheral neuropathy,
testing for paraneoplastic antibodies was done, revealing an
ANNA-1 titer of 1:7680 (normal 1:240). Based on this
finding, mediastinoscopy with biopsy of station-7 lymph
nodes was performed, yielding the diagnosis of limited stage
small cell carcinoma.
The patient subsequently underwent comprehensive
neurologic evaluation, which indicated the presence of
autoimmune gastrointestinal dysmotility and peripheral
neuropathy. He was treated with multiple courses of intra-
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venous immune globulin, chemotherapy consisting of four
cycles of carboplatin and etoposide, radiation therapy, and
low-dose prednisone. He experienced significant improve-
ment in appetite and diarrhea. His weight increased from
50 to 67 kg. Therapy was also associated with significant
improvement in his ataxic gait and peripheral neuropathy.
At the most recent follow-up, 2 years since the onset of
symptoms, he has no evidence of local small cell cancer
progression or metastases.
DISCUSSION
PET scanning in small cell carcinoma is associated with
avid FDG uptake,2 and is considered a very sensitive imaging
test in excluding small cell cancer in patients with indeter-
minate pulmonary nodules greater than 7 mm in size, and/or
mediastinal lymphadenopathy. The current case illustrates a
potential pitfall with the use of PET imaging in thoracic small
cell cancer associated with paraneoplastic syndromes, and
illustrates the diagnostic challenge in this unusual subgroup
of small cell cancer patients in whom the imaging character-
istics may be different from those expected in other cancers,
which is not associated with autoimmune phenomena.
Paraneoplastic antibodies are associated with multiple
types of cancers. Most paraneoplastic disorders are thought to be
mediated by antibodies to “onconeural” antigens—antigens
shared by tumors and neural tissues.3 Although multiple anti-
bodies can coexist and produce varied neurologic syndromes,
the antibody ANNA-1 is highly associated with small cell
cancer.1 Type 1 antineuronal nuclear autoantibodies are classi-
cally associated with a sensory neuropathy, but various other
neuropathic symptoms, including GI dysmotility, are well de-
scribed.1,4
Although most patients with small cell carcinoma
present with extensive-stage disease and have an aggres-
sive disease course, our patient presented with limited-
stage disease and, to date, has had a relatively indolent
clinical course. This is consistent with a previous report
that patients with small cell cancer and accompanying
paraneoplastic syndromes frequently present with disease
confined to the mediastinum.1 Similarly, no detectable
malignancy was found in a significant minority of patients
(33 of 200) with anti-ANNA-1 (also known as anti-Hu)
autoantibodies.5 This suggests that paraneoplastic antibod-
ies may exert a beneficial antitumor effect. Consistent with
this, a patient with squamous cell lung carcinoma and a
paraneoplastic syndrome associated with anti-ANNA-1
autoantibodies experienced a spontaneous complete re-
gression of her cancer.6 These reports support the hypoth-
esis that in small cell cancer associated with autoimmune
phenomena, the production of autoantibodies directed
against tumor-associated antigens may result in a benefi-
cial host immune antitumor response.
The diagnosis of small cell carcinoma must be made by
tissue biopsy; however, the decision to biopsy is usually
guided by chest imaging findings. In the diagnostic evalua-
tion of suspected lung cancer, chest CT and PET provide
distinct and complimentary information to the clinician. Ex-
perience with the use of PET in lung cancer diagnosis and
staging is substantial; however, most studies describing im-
aging characteristics in lung cancer have focused on non-
small cell lung cancer and the imaging characteristics of
small cell lung cancer, particularly the subset associated with
autoimmune syndromes, is not as well-defined. In one study
evaluating PET for primary staging of small cell lung carci-
noma, marked accumulation of FDG was detected in the
primary tumors of 120 of 120 serial patients (sensitivity
100%).7 Nevertheless, it does not appear that any of the
patients with small cell cancer in that series had paraneoplas-
tic complications. A recent study reported the use of PET and
CT as imaging modalities in patients with known paraneo-
plastic syndromes but unknown primary malignancy.8 In that
case series of 13 patients, FDG-PET alone had a sensitivity of
90% in tumor detection, and the combined sensitivity of PET
and CT imaging was 100%. There are some patients with
autoimmune paraneoplastic syndromes associated with small
FIGURE 1. A, Representative images from the chest com-
puted tomography (CT) performed at the onset of symp-
toms showing a 9-mm right lower lobe pulmonary nodule
and lymphadenopathy in the subcarinal lymph nodes with a
maximal diameter of 2 cm. B, Chest CT obtained approxi-
mately 6 months after the initial CT, demonstrating stability
in the right lower lobe nodule and regression of the subcari-
nal adenopathy.
FIGURE 2. Fluorodeoxy-D-glucose-positron emission to-
mography (FDG-PET) images at the level of the right lower
lobe pulmonary nodule (left panel) and the subcarinal re-
gion (right panel) demonstrating minimal fluorodeoxy-D-
glucose (FDG) accumulation in the subcarinal adenopathy
and the nodule (maximal SUV uptake 1.4).
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cancer whose imaging studies with body CT and PET will not
reveal a potential primary tumor for months and even years
after the onset of the paraneoplastic syndrome (unpublished
observations). Careful follow-up with serial CT and PET
seem to be pertinent in patients with paraneoplastic autoim-
mune syndromes without evident primary cancer.
Although unique, this case report suggests that the
natural biology and radiographic characteristics of small
cell lung cancer associated with paraneoplastic autoim-
mune phenomena is different from other lung carcinomas.
Radiographic studies should be interpreted with caution in
this specific subgroup of lung cancer, and radiographic
characteristics reported to occur in the nonimmunologi-
cally active type of lung cancer may not necessarily be
extrapolated to patients with paraneoplastic immune small
cell cancers. This case was surprising in that neither CT
nor PET imaging was suggestive of small cell cancer and
diagnosis was only possible by biopsy. In patients with
autoimmune paraneoplastic syndromes that are thought to
be associated with occult malignancy, imaging studies
need to be interpreted with caution.
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